Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALPL | P05186 | 1/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | ALPG | P10696 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6306047 | 0.95 | CYP2C19 (0.59) | CYP2C19CYP1A2CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL28965534 | 0.92 | CYP2C19 (0.57) | CYP2C19CYP1A2CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL3078147 | 0.89 | CYP2C19 (0.64) | CYP2C19CYP1A2CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL8748290 | 0.87 | CYP2C19 (0.48) | CYP2C19CYP1A2CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL5979449 | 0.86 | CYP2C19 (0.52) | CYP2C19CYP1A2CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL10332678 | 0.86 | CYP2C19 (0.52) | CYP2C19CYP1A2CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL4088646 | 0.86 | CYP2C19 (0.57) | CYP2C19CYP1A2CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL10993775 | 0.86 | CYP2C19 (0.52) | CYP2C19CYP1A2CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL2561339 | 0.86 | CYP2C19 (0.52) | CYP2C19CYP1A2CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL6042549 | 0.86 | CYP2C19 (0.52) | CYP2C19CYP1A2CYP2D6CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257130-A1 | Compositions and Methods for Treatment of Renin-Angiotensin Aldosterone System (RAAS)- Related Disorders | CARMEL BIOSCIENCES, INC. | 2011-10-20 | — | — | US | disclosed |
| US-20110257130-A1 | Compositions and Methods for Treatment of Renin-Angiotensin Aldosterone System (RAAS)- Related Disorders | CARMEL BIOSCIENCES, INC. | 2011-10-20 | — | — | US | disclosed |
| WO-2010045575-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENIN-ANGIOTENSIN ALDOSTERONE SYSTEM (RAAS)-RELATED DISORDERS | INVASC THERAPEUTICS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| US-5095091-A | High molecular weight | SHELL OIL COMPANY (US) | 1992-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257130-A1 | Compositions and Methods for Treatment of Renin-Angiotensin Aldosterone System (RAAS)- Related Disorders | REN, ACE, AGT | CYP2C19 1036/4885CYP1A2 885/4885CYP2D6 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.